BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aviva Systems Biology Announces Expansion Of ChIP-DSL Services; Creates New Opportunities For Drug Discovery And Disease Prevention Via Gene Transcription Regulation Assay


1/25/2007 10:20:43 AM

SAN DIEGO, Jan. 24 /PRNewswire/ -- Infused with $4-million in new funding from investors, Aviva Systems Biology (ASB), a leader in developing, manufacturing and marketing tools for gene transcription regulation research, plans to expand its ChIP-DSL services for genome wide detection of promoter- transcription factor interactions, the company announced today.

"Our ability to couple our microarray-based ChIP-DSL platform for genome wide promoter-transcription factor detection with our high throughput antibody production capabilities offers our customers a complete and unique package for transcription regulation assays. This systems-based approach to understanding transcriptional regulation, epigenetic modifications and DNA methylation should provide new and significant insights into biomarker and drug discovery efforts with regards to cancer, diabetes and other disease states," says Julian Yuan, ASB's CEO.

ASB recently relocated to a new facility that will significantly enhance its ability to provide a diverse range of ChIP-DSL promoter services to a broad range of customers.

ChIP-DSL platform is based on technology invented by Dr. Xiangdong Fu, a professor at UC-San Diego. It's licensed exclusively by ASB in 2004.

About Aviva Systems Biology:

Based in San Diego, Calif., ASB is a leader in developing, manufacturing and marketing tools for gene transcription regulation research. The company introduced its ChIP-DSL service in August, 2006 to screen 20,000 human promoters in a single array format. ASB also generates family-oriented high throughput antibodies and additional reagents for other important research areas.

Contact: To learn more about ASB or ChIP-DSL, email Dr. Jeffrey Falk, Director of Technology Applications, jfalk@avivasysbio.com

Web Site: http://www.avivasysbio.com

Aviva Systems Biology

CONTACT: Dr. Jeffrey Falk, Director of Technology Applications of AvivaSystems Biology, +1-858-552-6979, jfalk@avivasysbio.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES